Tang Yan, Wu Fang, Hu Chunhong
Department of Oncology, Second Xiangya Hospital, Central South University, Changsha 41001, China.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011 Jul;36(7):650-4. doi: 10.3969/j.issn.1672-7347.2011.07.012.
To determine the relation between the promoter methylation status of RUNX3 gene and clinicopathological parameters, prognosis of non-small cell lung cancer (NSCLC).
We collected 80 formalin-fixed paraffin-embedded lung cancer tissue samples from NSCLC patients who received postoperative adjuvant chemotherapy with cisplatin. Genomic DNA was extracted through phenol/chloroform extraction. The methylation status of RUNX3 was determined by nested methylation-specific PCR (nMSP). We investigated the pathological and prognostic characteristics of NSCLC stratified by methylation status.
The RUNX3 promoter methylation was observed in 20 of the 80 NSCLC samples (25.0%). Methylation of RUNX3 was more frequent in adenocarcinomas (36%) than in squamous cell carcinomas (11%) (P=0.020). In multivariate Logistic regression, positive RUNX3 methylation status (P=0.011) was found to be independent disease-free survival factor as was N stage (P<0.001). Kaplan-Meier curves showed patients with RUNX3 methylation had a significantly poorer overall survival than those without methylation (P=0.003; log-rank test). In multivariate Cox proportional hazards regression analysis, RUNX3 methylation (RR:2.345, 95% CI:1.30-4.865, P=0.022) was a significant independent prognostic factor for the overall survival.
RUNX3 methylation is a significant independent prognostic factor for disease-free survival and overall survival.
确定RUNX3基因启动子甲基化状态与非小细胞肺癌（NSCLC）临床病理参数及预后之间的关系。
我们收集了80例接受顺铂术后辅助化疗的NSCLC患者的福尔马林固定石蜡包埋肺癌组织样本。通过酚/氯仿提取法提取基因组DNA。采用巢式甲基化特异性PCR（nMSP）检测RUNX3的甲基化状态。我们根据甲基化状态对NSCLC的病理和预后特征进行了研究。
80例NSCLC样本中有20例（25.0%）观察到RUNX3启动子甲基化。RUNX3甲基化在腺癌（36%）中比在鳞状细胞癌（11%）中更常见（P=0.020）。在多因素Logistic回归分析中，发现RUNX3甲基化阳性状态（P=0.011）与N分期（P<0.001）一样是独立的无病生存因素。Kaplan-Meier曲线显示，RUNX3甲基化患者的总生存期明显低于未甲基化患者（P=0.003；对数秩检验）。在多因素Cox比例风险回归分析中，RUNX3甲基化（RR：2.345，95%CI：1.30 - 4.865，P=0.022）是总生存期的显著独立预后因素。
RUNX3甲基化是无病生存期和总生存期的显著独立预后因素。
